Syros Pharmaceuticals (SYRS) Revenue & Revenue Breakdown
Syros Pharmaceuticals Revenue Highlights
Latest Revenue (Y)
$9.94M
Syros Pharmaceuticals Revenue by Period
Syros Pharmaceuticals Revenue by Year
Date | Revenue | Change |
---|---|---|
2023-12-31 | $9.94M | -33.23% |
2022-12-31 | $14.88M | -36.65% |
2021-12-31 | $23.49M | 55.62% |
2020-12-31 | $15.09M | 661.50% |
2019-12-31 | $1.98M | -3.32% |
2018-12-31 | $2.05M | 86.19% |
2017-12-31 | $1.10M | 247.32% |
2016-12-31 | $317.00K | - |
2015-12-31 | $317.00K | 100.00% |
2014-12-31 | - | - |
Syros Pharmaceuticals Revenue by Quarter
Date | Revenue | Change |
---|---|---|
2024-09-30 | - | 100.00% |
2024-06-30 | - | 100.00% |
2024-03-31 | - | -100.00% |
2023-12-31 | $386.00K | -89.74% |
2023-09-30 | $3.76M | 32.79% |
2023-06-30 | $2.83M | -4.10% |
2023-03-31 | $2.95M | -154.03% |
2022-12-31 | $-5.47M | -240.50% |
2022-09-30 | $3.89M | -38.00% |
2022-06-30 | $6.28M | 14.80% |
2022-03-31 | $5.47M | -29.93% |
2021-12-31 | $7.80M | 36.95% |
2021-09-30 | $5.70M | 10.36% |
2021-06-30 | $5.16M | 6.94% |
2021-03-31 | $4.83M | -15.30% |
2020-12-31 | $5.70M | 48.88% |
2020-09-30 | $3.83M | 20.08% |
2020-06-30 | $3.19M | 34.01% |
2020-03-31 | $2.38M | 368.31% |
2019-12-31 | $508.00K | -8.96% |
2019-09-30 | $558.00K | 20.78% |
2019-06-30 | $462.00K | 1.76% |
2019-03-31 | $454.00K | -49.16% |
2018-12-31 | $893.00K | 116.75% |
2018-09-30 | $412.00K | 9.87% |
2018-06-30 | $375.00K | 1.35% |
2018-03-31 | $370.00K | 100.00% |
2017-12-31 | - | 100.00% |
2017-09-30 | - | 100.00% |
2017-06-30 | - | -100.00% |
2017-03-31 | $1.10M | 247.32% |
2016-12-31 | $317.00K | 100.00% |
2016-09-30 | - | 100.00% |
2016-06-30 | - | 100.00% |
2016-03-31 | - | 100.00% |
2015-12-31 | - | 100.00% |
2015-09-30 | - | -100.00% |
2015-06-30 | $317.00K | 100.00% |
2015-03-31 | - | - |
Syros Pharmaceuticals Peer Comparison by Revenue
Ticker | Company | Last Year Revenue | Last Quarter Revenue |
---|---|---|---|
CHRS | Coherus BioSciences | $257.24M | $64.98M |
XNCR | Xencor | $168.34M | $16.96M |
SPRO | Spero Therapeutics | $96.73M | $10.20M |
RGNX | REGENXBIO | $90.24M | $22.30M |
IDYA | IDEAYA Biosciences | $23.39M | - |
SYRS | Syros Pharmaceuticals | $9.94M | - |
STOK | Stoke Therapeutics | $8.78M | $4.22M |
BOLT | Bolt Biotherapeutics | $7.88M | $1.27M |
KZR | Kezar Life Sciences | $7.00M | - |
KRON | Kronos Bio | $6.29M | $2.69M |
CRNX | Crinetics Pharmaceuticals | $4.01M | $640.00K |
FIXX | Q32 Bio | $1.16M | - |
KROS | Keros Therapeutics | $151.00K | $83.00K |
BDTX | Black Diamond Therapeutics | - | - |
GRCL | Gracell Bio | - | - |
PASG | Passage Bio | - | - |
SNDX | Syndax Pharmaceuticals | - | $3.50M |
RNXT | RenovoRx | - | - |
NLTX | Neurogene | - | - |
LRMR | Larimar Therapeutics | - | - |
SRZN | Surrozen | - | - |
QNRX | Quoin Pharmaceuticals | - | - |
KTTA | Pasithea Therapeutics | - | - |
SYRS Revenue FAQ
What is Syros Pharmaceuticals’s yearly revenue?
Syros Pharmaceuticals's yearly revenue for 2023 was $9.94M, representing a decrease of -33.23% compared to 2022. The company's yearly revenue for 2022 was $14.88M, representing a decrease of -36.65% compared to 2021. SYRS's yearly revenue for 2021 was $23.49M, representing an increase of 55.62% compared to 2020.
What is Syros Pharmaceuticals’s quarterly revenue?
Syros Pharmaceuticals's quarterly revenue for Q3 2024 was $0, a 100.00% increase from the previous quarter (Q2 2024), and a -100.00% decrease year-over-year (Q3 2023). The company's quarterly revenue for Q2 2024 was $0, a 100.00% increase from the previous quarter (Q1 2024), and a -100.00% decrease year-over-year (Q2 2023). SYRS's quarterly revenue for Q1 2024 was $0, a -100.00% decrease from the previous quarter (Q4 2023), and a -100.00% decrease year-over-year (Q1 2023).
What is Syros Pharmaceuticals’s revenue growth rate?
Syros Pharmaceuticals's revenue growth rate for the last 3 years (2021-2023) was -57.70%, and for the last 5 years (2019-2023) was 401.31%.